Hematologic Malignancy
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
CI-CAN-00000765Explore in graph →
Hematologic298 active trials6 approved drugs47 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000765Explore in graph →
Clinical trials
1,406 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (273)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05828589 | A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies | terminated | Phase 1 | 51 | BeOne MedicinesINDUSTRY | 4 | Jul 14, 2026 | clinicaltrials |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | terminated | Phase 1 | 84 | MEI Pharma, Inc.INDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04809467 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL)(topMIND) |
| terminated |
| Phase 1 / Phase 2 |
| 54 |
| Incyte CorporationINDUSTRY |
| 7 |
| Feb 4, 2026 |
| clinicaltrials |
| NCT05317936 | Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax | terminated | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT04240704 | Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL | terminated | Phase 1 | 25 | Novartis PharmaceuticalsINDUSTRY | 7 | Oct 10, 2025 | clinicaltrials |
| NCT06343376 | Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies | terminated | Phase 1 | 1 | Roswell Park Cancer InstituteOTHER | 1 | Aug 3, 2025 | clinicaltrials |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL | terminated | Phase 1 | 55 | Biomea Fusion Inc.INDUSTRY | 5 | Jul 3, 2025 | clinicaltrials |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia(CORONADO CLL) | terminated | Phase 1 / Phase 2 | 5 | University of UtahOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT03400176 | VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib | terminated | Phase 1 | 39 | Novartis PharmaceuticalsINDUSTRY | 1 | May 16, 2025 | clinicaltrials |
| NCT01352312 | Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma | terminated | Phase 1 | 10 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03492125 | A Study Of The Selective PKC-β Inhibitor MS- 553 | terminated | Phase 1 / Phase 2 | 60 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers | terminated | Phase 1 | 272 | IGM Biosciences, Inc.INDUSTRY | 5 | Mar 28, 2025 | clinicaltrials |
| NCT04419389 | APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)(R/R) | terminated | Phase 1 / Phase 2 | 1 | Aprea TherapeuticsINDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03893682 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | terminated | Phase 1 | 36 | Aptose Biosciences Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04887259 | Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML | terminated | Phase 1 | 16 | Lava TherapeuticsINDUSTRY | 4 | Jan 27, 2025 | clinicaltrials |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas | terminated | Phase 1 / Phase 2 | 46 | GenmabINDUSTRY | 5 | Oct 24, 2024 | clinicaltrials |
| NCT03884829 | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS | terminated | Phase 1 | 7 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05094206 | CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies | terminated | Phase 1 | 4 | Medical College of WisconsinOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04806035 | Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | terminated | Phase 1 | 21 | TG Therapeutics, Inc.INDUSTRY | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05360238 | Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL | terminated | Phase 1 / Phase 2 | 20 | Mustang BioINDUSTRY | 1 | Jul 22, 2024 | clinicaltrials |
| NCT03671590 | Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | terminated | Phase 1 | 172 | TG Therapeutics, Inc.INDUSTRY | 2 | Jul 19, 2024 | clinicaltrials |
| NCT05272813 | A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL | terminated | Phase 1 / Phase 2 | 13 | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT05720052 | A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 8 | MingSight Pharmaceuticals, IncINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03151057 | Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies | terminated | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | terminated | Phase 1 | 3 | Stanford UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04978779 | A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome | terminated | Phase 1 | 6 | Vincerx Pharma, Inc.INDUSTRY | 2 | Nov 18, 2023 | clinicaltrials |
| NCT03572634 | Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL | terminated | Phase 1 / Phase 2 | 3 | Sumitomo Pharma America, Inc.INDUSTRY | 1 | Nov 9, 2023 | clinicaltrials |
| NCT04245722 | FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies | terminated | Phase 1 | 98 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05144347 | Study of XL114 in Subjects With Non-Hodgkin's Lymphoma | terminated | Phase 1 | 2 | ExelixisINDUSTRY | 1 | Jul 11, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT02914938 | A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma | terminated | Phase 1 | 97 | MEI Pharma, Inc.INDUSTRY | 2 | May 9, 2023 | clinicaltrials |
| NCT00558961 | Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients(GL-CLB-001) | terminated | Phase 1 / Phase 2 | 13 | Jewish General HospitalOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT02292225 | Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) | terminated | Phase 1 | 3 | SecuraBioINDUSTRY | 2 | Feb 27, 2023 | clinicaltrials |
| NCT04504708 | Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies | terminated | Phase 1 / Phase 2 | 6 | Hangzhou Zenshine Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | terminated | Phase 1 | 21 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 31, 2022 | clinicaltrials |
| NCT03379051 | Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | terminated | Phase 1 / Phase 2 | 78 | TG Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT01744912 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | terminated | Phase 1 | 10 | TG Therapeutics, Inc.INDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04160195 | T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma | terminated | Phase 1 | 2 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04176913 | Study of LUCAR-20S in Patients With R/R NHL | terminated | Phase 1 | 7 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT01585688 | Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL | terminated | Phase 1 / Phase 2 | 13 | Gilead SciencesINDUSTRY | 1 | Oct 8, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT01728207 | Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL | terminated | Phase 1 | 30 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| NCT03579888 | CD19-Specific T Cells Post AlloSCT | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2021 | clinicaltrials |
| NCT01644253 | Phase 1b Safety and Efficacy Study of TRU-016 | terminated | Phase 1 | 87 | Aptevo TherapeuticsINDUSTRY | 1 | May 20, 2021 | clinicaltrials |
| NCT01678443 | Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies | terminated | Phase 1 | 2 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT03601819 | Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders | terminated | Phase 1 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01300611 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation(USBTXA127CBT) | terminated | Phase 1 | 20 | Tarix PharmaceuticalsINDUSTRY | 1 | Dec 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2026source: clinicaltrials